JPMorgan raised the firm’s price target on AnaptysBio (ANAB) to $42 from $36 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- Cautious Hold Rating on AnaptysBio Amid Mixed Clinical Trial Results and Strategic Uncertainties
- AnaptysBio price target raised to $52 from $36 at Guggenheim
- AnaptysBio: Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Cautious Hold Rating on AnaptysBio Amid Uncertain Clinical Trial Outcomes and Strategic Decisions
- AnaptysBio Reports Strong Progress in Clinical Trials
Questions or Comments about the article? Write to editor@tipranks.com